MARKET

ATHX

ATHX

Athersys Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2548
-0.0202
-7.35%
After Hours: 0.2600 +0.0052 +2.04% 19:50 06/24 EDT
OPEN
0.2651
PREV CLOSE
0.2750
HIGH
0.2744
LOW
0.2525
VOLUME
26.35M
TURNOVER
0
52 WEEK HIGH
1.810
52 WEEK LOW
0.1800
MARKET CAP
65.64M
P/E (TTM)
-0.7182
1D
5D
1M
3M
1Y
5Y
24 Stocks Moving in Tuesday's Pre-Market Session
Gainers Valneva SE (NASDAQ: VALN) shares rose 83.6% to $25.18  in pre-market trading following Pfizer agreement to acquire an 8.1% stake.
Benzinga · 5d ago
Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures
CLEVELAND, Ohio, June 21, 2022--In connection with the Company’s cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from 10 to 5 members.
Business Wire · 5d ago
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Benzinga · 5d ago
Athersys shares rebound somewhat since falling by two-thirds on clinical trial results
Shares of Athersys Inc. have rebounded since losing two-thirds of their value last month after the Cleveland company announced clinical trial results that disappointed some investors. In mid-May, the regenerative medicine company reported that MultiStem —...
American City Business Journals · 06/17 18:55
33 Stocks Moving In Friday's Mid-Day Session
 Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.
Benzinga · 06/17 16:12
21 Stocks Moving in Friday's Pre-Market Session
Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday.
Benzinga · 06/17 09:51
30 Stocks Moving in Monday's Pre-Market Session
Gainers G Medical Innovations Holdings Ltd (NASDAQ: GMVD) rose 53.6% to $0.5301 in pre-market trading after dropping more than 28% on Friday.
Benzinga · 06/13 10:35
Athersys to ask shareholders to approve reverse stock split
The reverse split would help Athersys meet the minimum share price required for listing by the Nasdaq Stock Market.
American City Business Journals · 06/09 17:02
More
No Data
Learn about the latest financial forecast of ATHX. Analyze the recent business situations of Athersys Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
0.00%Hold
66.67%Under-perform
0.00%Sell
Analyst Price Target
The average ATHX stock price target is 1.117 with a high estimate of 3.000 and a low estimate of 0.1000.
High3.000
Average1.117
Low0.1000
Current 0.2548
EPS
Actual
Estimate
-0.08-0.06-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 182
Institutional Holdings: 62.63M
% Owned: 24.31%
Shares Outstanding: 257.60M
TypeInstitutionsShares
Increased
27
2.00M
New
16
4.06M
Decreased
35
4.10M
Sold Out
21
464.32K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
Ismail Kola
Chief Executive Officer/Director
Daniel Camardo
Chief Operating Officer
Maia Hansen
Director
Kenneth Traub
Independent Director
Jane Wasman
Independent Director
Jack Wyszomierski
No Data
No Data
About ATHX
Athersys, Inc. is a biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product. The MultiStem cell therapy includes the treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is a biologic product that is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The Company is conducting Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The Company's programs in the clinical development-stage include ischemic stroke, Acute respiratory distress syndrome (ARDS) and trauma.

Webull offers kinds of Athersys Inc stock information, including NASDAQ:ATHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHX stock methods without spending real money on the virtual paper trading platform.